Objective: To investigate body fluids of patients with undiagnosed leukodystrophies using in vitro 1 H-NMR spectroscopy (H-NMRS).
METHODS Standard protocol approvals, registrations, and patient consents. Eighty-three children and adults from 2 referral centers for neurogenetics and neurometabolism were enrolled in clinical protocols approved by the ethics committees of the National Institutes of Neurological Disorders and Stroke, Bethesda, Maryland, and the Radboud University Nijmegen Medical Center, The Netherlands. Written informed consent was obtained from all patients or their legal guardians.
Patients. Patients with leukodystrophies of unknown etiologies (n ϭ 41) were classified as hypomyelinating (n ϭ 27) or demyelinating (n ϭ 10) leukodystrophies or delayed myelination (n ϭ 4) according to the pattern on brain MRI. The disease control group consisted of 42 patients with leukodystrophies caused by known genes (PLP, eIF2B5, GFAP, GBE1, ABCD1, GALC, ASPA, ALDH3A2, ARSA, D2HGDH, DARS2) or defined leukodystrophy syndromes of unknown etiologies (hypomyelination hypogonadotropic hypogonadism and hypodontia syndrome, leukodystrophy with calcification and cysts, cerebellar ataxia with increased cerebrospinal free sialic acid).
Methods.
To identify new metabolic abnormalities, frozen urine and CSF (stored at Ϫ80°C) were prepared for 1 H-NMR spectroscopy (H-NMRS) with minimal handling 2 as part of a cross-sectional study. In addition to H-NMRS, urinary sialic acid levels were determined by quantitative colorimetric assay 2 and compared with urine samples from age-matched controls. Sialic acid was also measured in fibroblasts as described. 2 All exons of the SLC17A5 gene (GenBank NM_012434) were amplified from the patient's genomic DNA using specific intronic primers.
RESULTS

Increase of free sialic acid in the CSF or urine of 6 patients leading to the diagnosis of SASD.
Among the cohort of 41 patients with leukodystrophies of unknown etiology, high-resolution in vitro H-NMR spectroscopy of CSF revealed an increased concentration of free sialic acid in 5 patients, including 2 siblings previously reported (table). Free sialic acid presents as a prominent singlet resonance at 2.05 ppm and other resonances at 1.85 and 2.26 ppm in 1-dimensional NMRS (figure) with characteristic cross peaks in 2-dimensional correlation spectroscopy (COSY) NMR spectroscopy. 2 Increase of free sialic acid was also found in the urine of 3 of the 5 patients, as well as in the urine of a sixth patient for which the level of CSF free sialic acid level was consid- ered to be within the normal range (table) . Free sialic acid in fibroblasts was found to be increased in the 4 patients who were tested. The increase of free sialic acid in the CSF or urine or both suggested the diagnosis of SASD. SLC17A5 sequencing revealed known homozygous or compound heterozygous mutations in all 6 patients (table) . The clinical and brain MRI characteristics of the patients are summarized in the table. The prevalence of patients with SASD in our cohort of patients with hypomyelination was 22% (6/27).
Increase of NAAG in the CSF of patients with SASD.
In vitro H-NMR spectroscopy of CSF revealed a wide range of NAAG increase in the CSF of all 6 patients with SASD (table) . NAAG presents as a prominent singlet resonance at 2.04 ppm and smaller resonances at 2.85 (AB system), 2.01, 2.23, 2.48, 4.44, and 4.72 ppm (multiplet resonances) (figure) with characteristic cross peaks in 2-dimensional COSY NMR spectroscopy. 3 We confirmed the increase of NAAG in patients with PLP mutations (n ϭ 2). However, increased levels of CSF NAAG were not seen in patients with other hypomyelinating disorders, such as eIF2B5 mutations, in patients with a demyelinating brain pattern or delayed myelination. DISCUSSION We report 6 patients with SASD presenting with an increase of NAAG in their CSF. We previously identified 2 patients with SASD with nor-mal urinary excretion of free sialic acid, 2 suggesting that SLC17A5 mutations should be considered in patients with hypomyelination despite the absence of sialuria. The current report reveals that patients with SASD can also present with normal free sialic acid levels in their CSF, emphasizing that the analysis of both urine and CSF is helpful in the screening of patients with free sialic acid-related diseases. Constant clinical features in our patients with SASD were cognitive impairment and thin corpus callosum (table). Thus, in the appropriate clinical and neuroimaging setting, the isolated increase of NAAG in CSF should also suggest SASD and lead to sequencing of SLC17A5. Of interest, we found a high prevalence of SASD in our cohort of patients with hypomyelination (22%).
Increased CSF NAAG has been reported in 3 other hypomyelinating disorders: Pelizaeus-Merzbacher disease due to PLP1 mutations, 4 Pelizaeus-Merzbacherlike disease 1 due to GJA12 mutations, 5 and a yet unidentified hypomyelinating disorder. 3 A mildly increased concentration of NAAG in CSF has been described in combination with highly increased concentrations of N-acetylaspartate (NAA) in a case of Canavan disease. 6 However, CSF NAAG was normal in a large cohort of patients with nonneurodegenerative neurologic conditions or white matter disease of other origin. 7 Despite what has been suggested in Pelizaeus-Merzbacher disease, 4 there seems to be no correlation between the levels of NAAG in patients' CSF and the severity of the SASD phenotype in our patient cohort. Interestingly, levels of free sialic acid do not correlate with clinical severity of SASD either.
NAAG is the most abundant neuropeptide in the CNS and is present in a number of cells, including oligodendrocytes. 8 It is synthesized by the enzyme NAAG synthase from NAA and glutamate and is degraded by peptidases, especially glutamate carboxypeptidase II (GCPII) that is present in the membrane of neurons, astrocytes, and Schwann cells and possibly oligodendrocytes. NAAG is an endogenous agonist of metabotropic glutamate receptor 3 and acts as a weak antagonist at the NMDA receptor. The mechanism of its increase in patients with hypomyelinating leukodystrophy is not known, but one can hypothesize that it results from a decrease in GCPII activity secondary to the glial cell abnormality present in these leukodystrophies. 3 This is supported by our observation that the increase of NAAG in the CSF of patients with SASD is not associated with an increase of NAA. However, despite a marked loss of oligodendrocytes, the levels of NAAG were normal in the CSF of our patients with Krabbe disease. Furthermore, it is unlikely that NAAG contributes to the hypomyelination phenotype observed in SASD. NAAG was indeed recently reported to have a negligible action on oligodendrocytes' NMDA receptors. 9 The increase of NAAG in the extracellular space resulting from inhibition of GCPII has also been shown to be neuroprotective. 10 In patients with undiagnosed leukodystrophies, increased free sialic acid in CSF or urine suggests the diagnosis of SASD. The frequent increase of CSF NAAG in SASD and in other hypomyelinating disorders makes it a marker of a subgroup of hypomyelinating disorders. NAAG is readily detectable by NMRS, a technique confirmed to be useful for the identification of biomarkers associated with white matter disease. 
Be Prepared for January 1 Change in Medicare Consultation Codes
The American Academy of Neurology (AAN) is committed to providing resources for members that will prepare them for upcoming changes to the Centers for Medicare and Medicaid Services' 2010 Physician Fee Schedule, which include the use of new practice-expense data and the elimination of payment for consultation codes as of January 1, 2010.
Look to these AAN resources to help you prepare for the January 1 change:
• FREE online tools and resources, including a link to a calculator to help you determine the financial effect of these changes to your practice.
• For a deeper understanding of the upcoming changes, the AAN is offering a recording of its December 8, 2009 , webinar led by coding experts. $149.
Visit www.aan.com/view/consults.
